Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 5/20 | 0.42 |
| ▸ | FNTB | P49356 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886588 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTKMT2AL3MBTL1TAS1R3 | |
| SCHEMBL6778269 | 0.88 | TAS1R3 (0.42) | ALDH1A1MAPTTAS1R3TAS1R1 | |
| SCHEMBL6778272 | 0.88 | TAS1R3 (0.42) | ALDH1A1MAPTTAS1R3TAS1R1 | |
| SCHEMBL6777939 | 0.85 | TAS1R3 (0.46) | TAS1R3TAS1R1 | |
| SCHEMBL6777938 | 0.85 | TAS1R3 (0.46) | TAS1R3TAS1R1 | |
| SCHEMBL6776375 | 0.83 | ADRB2 (0.41) | ALDH1A1MAPTKMT2A | |
| SCHEMBL6776372 | 0.83 | ADRB2 (0.41) | ALDH1A1MAPTKMT2A | |
| SCHEMBL6775900 | 0.80 | FNTA (0.61) | ALDH1A1MAPTKMT2AFNTAFNTB | |
| SCHEMBL6775897 | 0.80 | FNTA (0.61) | ALDH1A1MAPTKMT2AFNTAFNTB | |
| SCHEMBL8365758 | 0.78 | ALDH1A1 (0.53) | ALDH1A1MAPTKMT2AL3MBTL1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | ALDH1A1 1121/4885MAPT 4674/4885KMT2A 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.